Lyra Therapeutics, Inc (LYRA)

Etorro trading 970x250
Lyra Therapeutics, Inc (LYRA) Logo

About Lyra Therapeutics, Inc

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company’s XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts. Address: 480 Arsenal Way, Watertown, MA, United States, 02472

Lyra Therapeutics, Inc News and around…

Latest news about Lyra Therapeutics, Inc (LYRA) common stock and company :

Lyra Therapeutics to Present at Upcoming Virtual Investor Conferences
11 Nov, 2021 Yahoo! Finance

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that Maria Palasis, Ph.D., Lyra's President and Chief Executive Officer, will present in a virtual format at three upcoming investor conferences:

Lyra Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
09 Nov, 2021 Yahoo! Finance

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today reported financial results for the quarter ended September 30, 2021, and highlighted recent accomplishments.

Lyra Therapeutics to Report Third Quarter 2021 Financial Results on November 9
02 Nov, 2021 Yahoo! Finance

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues will report third quarter 2021 financial results on Tuesday, November 9, 2021 after the close of market. Lyra will host a conference call and live webcast at 4:30 p.m. ET on the same day to discuss the results and provide a business update.

Lyra Therapeutics Presents New Positive Phase 2 LANTERN 6-Month Follow-Up and LYR-210 Pharmacokinetic Data, and LANTERN Manuscript Wins Award at the 67th Annual Meeting of the American Rhinologic Society
04 Oct, 2021 Yahoo! Finance

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, announced that new, positive LYR-210 data from the LANTERN 6-month post-treatment evaluation and recently completed pharmacokinetic study, were the subject of two oral presentations at the 67th Annual Meeting of the American Rhinologic Society

Lyra Therapeutics Announces Publication of Positive LANTERN Results in the International Forum of Allergy & Rhinology
21 Sep, 2021 FinancialContent
Lyra Therapeutics Announces Four Abstracts Selected for Presentations at Upcoming ERS and ARS Meetings, Including New LANTERN 6-Month Follow-Up and Pharmacokinetic Data
20 Sep, 2021 FinancialContent

LYR-210 Pharmacokinetic Study Chosen as a Top Clinical Abstract at ARS

Lyra Therapeutics Appoints Jason Cavalier as Chief Financial Officer
13 Sep, 2021 FinancialContent

Seasoned investment banking executive brings extensive finance, partnering and M&A experience to the role

Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo™ Technology Platform in the American Journal of Rhinology & Allergy
09 Sep, 2021 FinancialContent
Lyra Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
07 Sep, 2021 FinancialContent
We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth
03 Sep, 2021 Yahoo! Finance

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

12 Health Care Stocks Moving In Wednesday's Intraday Session
01 Sep, 2021 FinancialContent

Gainers Neuronetics (NASDAQ:STIM) stock rose 16.51% to $7.83 during Wednesday's regular session. As of 12:30 EST, ...

The Math Shows FDM Can Go To $76
24 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Dow Jones Select MicroCap Index Fund ETF (FDM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $75.53 per unit.

Lyra Therapeutics to Host Virtual Chronic Rhinosinusitis KOL Event on August 31
17 Aug, 2021 FinancialContent
Lyra Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Accomplishments
09 Aug, 2021 FinancialContent
Earnings Scheduled For August 9, 2021
09 Aug, 2021 FinancialContent

Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 ...

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
08 Aug, 2021 FinancialContent

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader ...

The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
04 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Tuesday
03 Aug, 2021 FinancialContent

On Tuesday morning, 69 companies achieved new lows for the year. Intriguing Points: Las Vegas Sands ...

10 Stocks to Buy According to Neil Shahrestani’s Ikarian Capital
03 Aug, 2021 Yahoo! Finance

In this article, we will take a look at the 10 stocks to buy according to Neil Shahrestani’s Ikarian Capital. To skip our detailed analysis of Shahrestani’s history, hedge fund performance, and investment philosophy, go directly to the 5 Stocks to Buy According to Neil Shahrestani’s Ikarian Capital. Neil Shahrestani, MD, is the Chief Investment Officer, managing […]

The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
28 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
27 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Lyra Therapeutics to Report Second Quarter 2021 Financial Results on August 9
26 Jul, 2021 FinancialContent
Analysts See 27% Upside For FDM
21 Jul, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Dow Jones Select MicroCap Index Fund ETF (FDM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $74.79 per unit.

Lyra Therapeutics to Present at Upcoming Virtual Healthcare Conference
12 Jul, 2021 FinancialContent
Lyra Therapeutics Announces Positive Topline Results of Pharmacokinetic Study of LYR-210 in Patients with Chronic Rhinosinusitis
30 Jun, 2021 FinancialContent
Should I Avoid Lyra Therapeutics, Inc. (LYRA)?
23 Jun, 2021 Yahoo! Finance

In this article we will take a look at whether hedge funds think Lyra Therapeutics, Inc. (NASDAQ:LYRA) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips […]

The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway
23 Jun, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

62 Biggest Movers From Yesterday
10 Jun, 2021 FinancialContent

Gainers Aethlon Medical, Inc. (NASDAQ: AEMD) shares surged 388.2% to close at $10.79 on Wednesday in reaction to Zacks Article ...

48 Stocks Moving In Wednesday's Mid-Day Session
09 Jun, 2021 FinancialContent

Gainers Aethlon Medical, Inc. (NASDAQ: AEMD) shares jumped 371% to $10.41 in reaction to Zacks Article 'AEMD: First Ever In Vivo ...

The Daily Biotech Pulse: Lyra Gains On Positive Regulatory Outcome, FDA Nod For Pfizer's Prevnar Vaccine, Merck Inks COVID-19 Treatment Supply Deal With US
09 Jun, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Lyra Therapeutics, Inc (LYRA) is a NASDAQ Common Stock listed in , ,

970x250